Clinical evidence-based study on new-generation drug-eluting stent:everolimus-eluting stents(Xience Ⅴ)
- VernacularTitle:新一代药物洗脱支架依维莫司药物洗脱支架临床循证研究
- Author:
Wenjun GAO
;
Wenjie LIU
;
Yongsheng KE
- Publication Type:Journal Article
- Keywords:
coronary artery disease;
everolimus;
percutaneous transluminal coronary angioplasty;
stent
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2002;0(05):-
- CountryChina
- Language:Chinese
-
Abstract:
Percutaneous coronary intervention(PCI) has been a mainstay in the management of coronary artery disease since its introduction in the late 1970s.Bare-metal stents and,more recently,first-generation drug-eluting stents(DES),such as sirolimus-eluting(Cypher) and paclitaxel-eluting stents(Taxus),have further improved results of percutaneous coronary intervention by improving early results and reducing the risk of restenosis.There are currently debates on the safety of these first-generation DES,given the potential for late stent thrombosis which is a first-generation drug-eluting stent of the largest security issue,especially after discontinuation of dual antiplatelet therapy.Next-generation DES such as everolimus-eluting stents(Xience V) holds the promise of superior anti-restenosis efficacy as well as long-term safety.This review makes a presentation of the evidence-based clinical research according to everolimus-eluting stents(Xience Ⅴ).
